PARP1 and cancer: In line with this, loss of ALC1 was shown to enhance PARP trapping and promote hypersensitivity to PARPi in BRCA-deficient cells (72–74), suggesting that ALC1 could serve as a potential therapeutic target in BRCA-mutant cancers.